A- A A+

«One prick and then it´s done»: a mixed-methods exploratory study on intramuscular injection in heroin-assisted treatment. 

Meyer M, Eichenberger R, Strasser J, Dürsteler KM, Vogel M. 

Harm Reduct J. 2021 Dec 18;18(1):134. doi: 10.1186/s12954-021-00584-3. PMID: 34922561; PMCID: PMC8684658.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8684658/

USA. New Opioids Called Nitazenes May Be 20 Times Stronger Than Fentanyl

A potent synthetic opioid class called nitazenes has been discovered after people overdosed on them.

The nitazene class of medication was created over 60 years ago as a potential pain-relief medication, according to the WHOTrusted Source.

Medical experts say this opioid may be up to 20 times more powerful than fentanyl. (Healthline, USA, 08.12.2021)

https://www.healthline.com/health-news/new-opioids-called-nitazenes-may-be-20-times-stronger-than-fentanyl

Etazene induces developmental toxicity in vivo Danio rerio and in silico studies of new synthetic opioid derivative. 

Kurach Ł, Chłopaś-Konowałek A, Budzyńska B, Zawadzki M, Szpot P, Boguszewska-Czubara A. 

Sci Rep. 2021 Dec 20;11(1):24269. doi: 10.1038/s41598-021-03804-9. PMID: 34931035; PMCID: PMC8688443.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8688443/

Moderater Alkoholkonsum verlängert das Leben (doch) nicht

Greifswald – Moderater Alkoholkonsum ist nicht gesundheitsförderlich. Anderslautende Schlussfolgerungen aus der Vergangenheit sind wahrscheinlich auf methodische Mängel in den zugrundeliegenden Studien zurückzuführen. Das berichtet eine Arbeitsgruppe um Ulrich John aus der Abteilung für Präventionsforschung und Sozialmedizin am Institut für Community Medicine der Universitätsmedizin Greifswald in der Fachzeitschrift PLOS Medicine (2021; DOI: 10.1371/journal.pmed.1003819). (aerzteblatt.de, 07.01.2022)

https://www.aerzteblatt.de/nachrichten/129428/Moderater-Alkoholkonsum-verlaengert-das-Leben-(doch)-nicht

Trends in Buprenorphine Use in US Jails and Prisons From 2016 to 2021. 

Thakrar AP, Alexander GC, Saloner B. 

JAMA Netw Open. 2021 Dec 1;4(12):e2138807. doi: 10.1001/jamanetworkopen.2021.38807. PMID: 34905010; PMCID: PMC8672225.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8672225/

Rapid Transition to Buprenorphine in a Patient With Methadone-Related QTc Interval Prolongation. 

Brogdon H, Facer KL, Cox EJ, Carlson RH Jr, Wurzel JF 3rd. 

J Addict Med. 2021 Dec 3. doi: 10.1097/ADM.0000000000000935. Epub ahead of print. PMID: 34864786.

Abstract

https://pubmed.ncbi.nlm.nih.gov/34864786/

Opioid use disorder from poppy seed tea successfully treated with buprenorphine in primary care: a case report. 

Hagan S, Achtmeyer CE, Hood C, Hawkins EJ, Williams EC. 

Addict Sci Clin Pract. 2021 Dec 3;16(1):71. doi: 10.1186/s13722-021-00280-4. PMID: 34861895; PMCID: PMC8641214.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8641214/

Buprenorphine Dosage and Urine Quantitative Buprenorphine, Norbuprenorphine, and Creatinine Levels in an Office-Based Opioid Treatment Program. 

Furo H, Schwartz DG, Sullivan RW, Elkin PL. 

Subst Abuse. 2021 Dec 6;15:11782218211061749. doi: 10.1177/11782218211061749. PMID: 34898987; PMCID: PMC8655441.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8655441/

Transition From Full Mu Opioid Agonists to Buprenorphine in Opioid Dependent Patients-A Critical Review. 

Soyka M. 

Front Pharmacol. 2021 Nov 23;12:718811. doi: 10.3389/fphar.2021.718811. PMID: 34887748; PMCID: PMC8650116.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8650116/

"I don't want to take buprenorphine for the rest of my life": Acceptance and Commitment Therapy for a Client Struggling to Reduce Low-Dose Buprenorphine (a Hermeneutic Single-Case Efficacy Design). 

Shepherd K, Pritty B, Tickle A, Moghaddam N. 

Int J Ment Health Addict. 2021 Dec 20:1-24. doi: 10.1007/s11469-021-00729-2. Epub ahead of print. PMID: 34955695; PMCID: PMC8686789.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8686789/

Buprenorphine: Drug Safety Communication - FDA warns about dental problems with buprenorphine medicines dissolved in the mouth to treat opioid use disorder and pain 

AUDIENCE: Dentistry, Anesthesiology, Patient, Health Professional, Pharmacy

ISSUE: The FDA is warning that dental problems have been reported with medicines containing buprenorphine that are dissolved in the mouth. The dental problems, including tooth decay, cavities, oral infections, and loss of teeth, can be serious and have been reported even in patients with no history of dental issues. Despite these risks, buprenorphine is an important treatment option for opioid use disorder (OUD) and pain, and the benefits of these medicines clearly outweigh the risks. (FDA – U.S. Food and Drug Administration, USA, 12.01.2022)

https://www.fda.gov/safety/medical-product-safety-information/buprenorphine-drug-safety-communication-fda-warns-about-dental-problems-buprenorphine-medicines

Uncertainty and risk: A framework for understanding pricing in online drug markets. 

Munksgaard R, Tzanetakis M. 

Int J Drug Policy. 2021 Dec 10;101:103535. doi: 10.1016/j.drugpo.2021.103535. Epub ahead of print. PMID: 34902806.

https://www.sciencedirect.com/science/article/pii/S0955395921004539

Sleep Quality Improvements After MDMA-Assisted Psychotherapy for the Treatment of Posttraumatic Stress Disorder. 

Ponte L, Jerome L, Hamilton S, Mithoefer MC, Yazar-Klosinski BB, Vermetten E, Feduccia AA. 

J Trauma Stress. 2021 Aug;34(4):851-863. doi: 10.1002/jts.22696. Epub 2021 Jun 10. PMID: 34114250; PMCID: PMC8453707.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8453707/

Kanada. CCENDU Bulletin: Risks and Harms Associated with Nonmedical Benzodiazepines in the Unregulated Drug Supply in Canada

This bulletin summarizes the risks and harms associated with nonmedical benzodiazepines and benzodiazepine-like substances that are increasingly being identified in drugs on the unregulated market, particularly drugs sold as opioids. (Canadian Centre on
Substance Use and Addiction, Kanada, Dezember 2021)

https://ccsa.ca/ccendu-alerts-and-bulletins

Cannabis and Psychosis: Recent Epidemiological Findings Continuing the “Causality Debate”

Suhas Ganesh and Deepak Cyril D’Souza

American Journal of Psychiatry 2022 179:1, 8-10 

https://ajp.psychiatryonline.org/doi/10.1176/appi.ajp.2021.21111126

Implications of OPRM1 and CYP2B6 variants on treatment outcomes in methadone-maintained patients in Ontario: Exploring sex differences. 

Chawar C, Hillmer A, Lamri A, Kapczinski F, Thabane L, Pare G, et al. (2021) 

PLoS ONE 16(12): e0261201. doi.org/10.1371/journal.pone.0261201

https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0261201

Shifting North American drug markets and challenges for the system of care. 

Krausz RM, Westenberg JN, Mathew N, Budd G, Wong JSH, Tsang VWL, Vogel M, King C, Seethapathy V, Jang K, Choi F. 

Int J Ment Health Syst. 2021 Dec 20;15(1):86. doi: 10.1186/s13033-021-00512-9. PMID: 34930389; PMCID: PMC8685808.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8685808/

Transcranial Magnetic Stimulation for the Treatment of Cocaine Addiction: A Systematic Review. 

Torres-Castaño A, Rivero-Santana A, Perestelo-Pérez L, Duarte-Díaz A, Toledo-Chávarri A, Ramos-García V, Álvarez-Pérez Y, Cudeiro-Mazaira J, Padrón-González I, Serrano-Pérez P. 

J Clin Med. 2021 Nov 28;10(23):5595. doi: 10.3390/jcm10235595. PMID: 34884297; PMCID: PMC8658408.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8658408/

Ibrutinib as a potential therapeutic for cocaine use disorder. 

Huggett SB, Hatfield JS, Walters JD, McGeary JE, Welsh JW, Mackay TFC, Anholt RRH, Palmer RHC. 

Transl Psychiatry. 2021 Dec 8;11(1):623. doi: 10.1038/s41398-021-01737-5. PMID: 34880215; PMCID: PMC8654982.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8654982/

'Not at all what I had expected': Discontinuing treatment with extended-release naltrexone (XR-NTX): A qualitative study. 

Brenna IH, Marciuch A, Birkeland B, Veseth M, Røstad B, Løberg EM, Solli KK, Tanum L, Weimand B. 

J Subst Abuse Treat. 2021 Nov 27:108667. doi: 10.1016/j.jsat.2021.108667. Epub ahead of print. PMID: 34865937.

https://linkinghub.elsevier.com/retrieve/pii/S0740-5472(21)00393-7

Ayahuasca Technical Report

26 pages with all the latest research-based facts about ayahuasca, its uses, pharmacology, legal status and therapeutic effects, signed by 11 world-class experts and researchers.

The 2021 Ayahuasca Technical Report and fact sheets synthesize the currently available research on ayahuasca and are a reliable source of information on what is (and what is not) known about ayahuasca. (ICEERS - International Center for Ethnobotanical Education, Research, and Service, Spanien, 21.12.2021)

https://www.iceers.org/ayahuasca-technical-report/

Ketamine for the treatment of mental health and substance use disorders: Comprehensive systematic review. 

Walsh, Z., Mollaahmetoglu, O., Rootman, J., Golsof, S., Keeler, J., Marsh, B., . . . Morgan, C. (2022). 

BJPsych Open, 8(1), E19. doi:10.1192/bjo.2021.1061

https://www.cambridge.org/core/journals/bjpsych-open/article/ketamine-for-the-treatment-of-mental-health-and-substance-use-disorders-comprehensive-systematic-review/36E261BFA62CDA6459B88F7777415FDA#.Ycn724EbuAw.twitter

Webinar. Therapie auf Augenhöhe – wer sagt, wo es lang geht? 10.02.2022 - 18:00-18:45 Uhr

Die Behandlung von Abhängigkeiten stellt sowohl Ärzt:innen als auch Patient:innen vor die große Aufgabe, individuell geeignete Lösungen in vielen verschiedenen Bereichen des Therapiekonzeptes zu erarbeiten. In dieser Online-Fortbildung gehen Herr Dr. Naumann, Herr Professor Reimer und Herr Dirk Schäffer auf die damit verbundenen wichtigsten Fragen ein. Sie geben einen kurzen historischen Überblick über die Entstehung des Hilfesystems und beleuchten anschließend verschiedene Aspekte der Therapie aus verschiedenen Blickwinkeln. Als zentraler Punkt soll hierbei geklärt werden, ob und wie ein Schritt hin zu einer modernen, partizipativen und patientenorientierten Behandlung der Opioidabhängigkeit möglich ist.

Die Veranstaltung ist zur Zertifizierung bei der Bayerischen Landesärztekammer eingereicht. (StEP, Januar 2022)

https://step-initiative.de/webinar/therapie-auf-augenhoehe-wer-sagt-wo-es-lang-geht/

Virtual Solutions for Substance Use Care Conference 2022: Capacity, quality and integration across settings (January 25, 2022; 8am-4pm PST)

Th The healthcare system in general is struggling with a slow process of transition and change. The COVID-19 pandemic and other public health challenges showed that the current capacity and quality of care are insufficient. It is evident that we need a bigger variety and larger range of interventions and settings to address these crises and take care of the most vulnerable. Patients with high-risk substance use disorders are especially at risk of dying of an overdose and have significant issues accessing appropriate and effective care. (The University of British Columbia, Januar 2022)

https://acdresearch.med.ubc.ca/events/virtual-solutions-for-substance-use-care-conferences/virtual-solutions-for-substance-use-care-conference-2022/

Substance-Induced Psychoses: An Updated Literature Review. 

Fiorentini A, Cantù F, Crisanti C, Cereda G, Oldani L and Brambilla P (2021) 

Front. Psychiatry 12:694863. doi: 10.3389/fpsyt.2021.694863

https://www.frontiersin.org/articles/10.3389/fpsyt.2021.694863/full

Long-Acting Injectable Antipsychotic Treatment in Schizophrenia and Co-occurring Substance Use Disorders: A Systematic Review.

Coles AS, Knezevic D, George TP, Correll CU, Kane JM, Castle D. 

Front Psychiatry. 2021;12:808002. Published 2021 Dec 15. doi:10.3389/fpsyt.2021.808002

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8715086/

Acute pain and self-directed discharge among hospitalized patients with opioid-related diagnoses: a cohort study. 

Compton, P., Aronowitz, S.V., Klusaritz, H. et al.

Harm Reduct J 18, 131 (2021). doi.org/10.1186/s12954-021-00581-6

https://harmreductionjournal.biomedcentral.com/articles/10.1186/s12954-021-00581-6

Posttraumatische Belastungsstörung: Neue Praxisinformation erschienen

Hillienhof, Arne, Dtsch Arztebl 2021; 118(51-52): A-2465 / B-2021

https://www.aerzteblatt.de/archiv/222672

Effect of initiation of medications for opioid use disorder on hospitalization outcomes for endocarditis and osteomyelitis in a large private hospital system in the United States, 2014-18. 

Jo Y, Nosal R, Vittori A, Cordova L, Vandever C, Alvarez C, Bartholomew TS, Tookes HE. 

Addiction. 2021 Aug;116(8):2127-2134. doi: 10.1111/add.15393. Epub 2021 Jan 22. PMID: 33394516; PMCID: PMC8359423.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8359423/

Invasive Burkholderia cepacia Complex Infections among Persons Who Inject Drugs, Hong Kong, China, 2016-2019. 

Luk KS, Tsang YM, Ho AY, To WK, Wong BK, Wong MM, Wong YC. 

Emerg Infect Dis. 2021 Dec 14;28(2). doi: 10.3201/eid2802.210945. Epub ahead of print. PMID: 34906288.

https://wwwnc.cdc.gov/eid/article/28/2/21-0945_article